Biotech entity
Every one of those 1 sits in a single category, pharma. AGI is most often covered alongside Demis Hassabis, which appears in 1 of these 1 story. The tracked stories average 4 original sources each. AGI appears in 1 tracked Biotech story from February 18, 2026.
Last mentioned: Feb 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. AGI is most often covered alongside Demis Hassabis, which appears in 1 of these 1 story. The tracked stories average 4 original sources each. AGI appears in 1 tracked Biotech story from February 18, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 13 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering AGI. Shared-story counts are live from our verified record — not editorial picks.
Google DeepMind CEO Demis Hassabis predicts Artificial General Intelligence (AGI) could arrive within five to eight years, ushering in a 'golden era of science' for drug discovery. While the timeline suggests a radical acceleration of biological engineering, Hassabis issued urgent warnings regarding biosecurity risks as AI systems gain autonomous capabilities.
Source: freepressjournal.in · moneycontrol.com
AGI is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
